BACKGROUND: Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand. METHODS: A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16-70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months. RESULTS: At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00). CONCLUSION:Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.
RCT Entities:
BACKGROUND: Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand. METHODS: A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16-70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months. RESULTS: At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00). CONCLUSION:Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.
Authors: D E Jorenby; S J Leischow; M A Nides; S I Rennard; J A Johnston; A R Hughes; S S Smith; M L Muramoto; D M Daughton; K Doan; M C Fiore; T B Baker Journal: N Engl J Med Date: 1999-03-04 Impact factor: 91.245
Authors: D Tashkin; R Kanner; W Bailey; S Buist; P Anderson; M Nides; D Gonzales; G Dozier; M K Patel; B Jamerson Journal: Lancet Date: 2001-05-19 Impact factor: 79.321
Authors: R D Hurt; D P Sachs; E D Glover; K P Offord; J A Johnston; L C Dale; M A Khayrallah; D R Schroeder; P N Glover; C R Sullivan; I T Croghan; P M Sullivan Journal: N Engl J Med Date: 1997-10-23 Impact factor: 91.245
Authors: David J Maclaren; Katherine M Conigrave; Jan A Robertson; Rowena G Ivers; Sandra Eades; Alan R Clough Journal: Popul Health Metr Date: 2010-02-20
Authors: Mark J Eisenberg; Kristian B Filion; Daniel Yavin; Patrick Bélisle; Salvatore Mottillo; Lawrence Joseph; André Gervais; Jennifer O'Loughlin; Gilles Paradis; Stephane Rinfret; Louise Pilote Journal: CMAJ Date: 2008-07-15 Impact factor: 8.262
Authors: Michelle DiGiacomo; Patricia M Davidson; Penelope A Abbott; Joyce Davison; Louise Moore; Sandra C Thompson Journal: Int J Environ Res Public Health Date: 2011-01-31 Impact factor: 3.390
Authors: Julia V Marley; David Atkinson; Tracey Kitaura; Carmel Nelson; Dennis Gray; Sue Metcalf; Graeme P Maguire Journal: BMC Public Health Date: 2014-01-13 Impact factor: 3.295